This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
**The 2022 Sales Hiring Forecast has been released – check it out now!**. It’s time for the 6th installment of our annual sales hiring forecast. As there isn’t a hiring forecast specific for b2b sales roles, we started our own forecast in 2015 to help fill this gap. 2019 Sales Hiring in Review. 2020 Sales Hiring Forecast.
As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. Pfizer reaped $36.8bn from Comirnaty, the highest revenue generated from Covid-19 vaccine sales worldwide. YoY revenue growth.
It was an exceptional year for Moderna’s vaccine Spikevax, with forecast sales of $19.5bn in 2022. Currently, Spikevax is the second bestselling Covid-19 vaccine behind Pfizer’s Comirnaty, which is in the leading position, with forecast sales of $37bn in 2022.
GlobalData predicts Bristol-Myers Squibb’s Breyanzi and Gilead’s Yescarta are set to have high annual sales in the forecast period. It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7 Peak sales are anticipated to reach $1.3 billion in 2031.
The leading marketed CAR-T cell products, Gilead’s Yescarta (axicabtagene ciloleucel) and Novartis’ Kymriah (tisagenlecleucel), achieved $695m and $587m in sales respectively last year, demonstrating the high potential for sales of successful new cell therapies.
According to GlobalData’s Drugs database, there were 22 prophylactic vaccines in development for COVID-19 with sales forecasts available in H2 2022. According to GlobalData’s Drugs database, there were 22 prophylactic vaccines in development for COVID-19 with sales forecasts available in H2 2022.
Most seasoned medical sales representatives have carried several different products or services over their careers. Between emerging technologies, expiring patents, and ever-changing insurance coverage, the role of a medical sales professional is to constantly adapt and learn new things. Gives you an area of expertise.
That’s especially been the case in the sales arena where, according to a recent McKinsey report , the effect of ChatGPT and similar generative AI technologies has been nothing short of revolutionary. For example, look at the following two prompts (you might want to try them for yourself): Write a sales email for our ABC Widget product.
Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall. CMS negotiation may lead to additional savings for beneficiaries and for the Medicare program.
These acquisitions could possibly add a minimum of $1bn in sales of Viatris by 2028. This will form the foundation to establish a leading international ophthalmology franchise, expediting work for addressing the unmet needs in the area of ophthalmic diseases. Viatris plans to finance these purchases in cash.
In 2019, Daiichi Sankyo entered a global development and commercialisation agreement with AstraZeneca for Daiichi Sankyo’s lead antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), in a deal worth $6.9bn. GlobalData estimates that global annual sales for datopotamab deruxtecan in the NSCLC setting will exceed $500m in 2028.
According to McKinsey, global oncology sales are expected to hit $250 billion by 2024 and, despite the impact of COVID-19, the number of clinical trials starts reached record highs in 2021, stated IQVIA. billion in revenue last year.
This therapy is currently in Phase II development and is expected to launch in the US and 5EU in 2027 and 2028, respectively. of 7MM sales. GlobalData’s report also covers a third pipeline candidate, quinagolide, a dopamine receptor antagonist being developed by Ferring Pharmaceuticals.
Recruiting and retaining talent is one of the biggest challenges facing the industry now through 2028, as the US Bureau of Labor Statistics expects life, physical, and social sciences to grow 7%. Address mental health early: Burnout is common amongst professionals in the pharmaceutical industry and leads to high turnover.
billion by 2028. Keep reading to learn 10 roofing sales tips you can use to drive more revenue in 2023. These 10 roofing sales tips will put you and your sales team in the best position to succeed. These 10 roofing sales tips will put you and your sales team in the best position to succeed.
The latest report – in the Wall Street Journal – says that “advanced talks” are underway that could lead to a $200-plus per share offer that would value Seagen at a massive $40 billion, $10 billion more than earlier estimates.
Antigens such as CD123 and CD33, despite being markers of myeloid cells, are shared with their healthy counterparts, and myeloablation following their depletion often leads to detrimental clinical outcomes. If approved, it could reach sales of $158 million in the 8MM (US, France, Germany, Italy, Spain, the UK, Japan, and China) by 2031.
It also has products from other leading manufacturers. Brasseler USA is one of the leading dental instrumentation companies popular for restorative, orthodontic, endodontic, and oral surgery equipment. They follow a direct sales model and sell their products directly to the customer, without any interference from any middlemen.
According to the ClinicalTrials.gov trial registry, as of April 2022 3 there were 231 bsAbs in clinical trials and a recent industry report 4 predicts the global market revenue for these products will exceed $20 billion by 2028. Figure 1: Example of bi-specific formats. Tools such as the Lonza High?Throughput Nat Rev Drug Discov.
The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.
This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active. Non-small cell lung cancer leads as the indication with the highest number of PROTACs in the pipeline, currently sitting at 11 preclinical candidates.
Pharma, formulary decision-makers, and contracting specialists must now track exact dates when drugs became available, then track the difference between average sales price (ASP) and Maximum Fair Price (MFP) to ensure provider reimbursement is correct.”
Market Competition: Another similarity that biosimilars have to generics is that there can be multiple biosimilars for the same reference product, leading to competition for shares in the market. link] The post Biosimilars: The Future of Affordable Biologic Therapies appeared first on Pharma Sales Training.
According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. These drugs are set to make a combined $4.34bn in sales in 2028.
For 20 of the leading biopharmaceutical companies, the second quarter (Q2) of 2023 has brought an aggregate market capitalisation growth of 2.3 Lilly completes biopharma acquisitions GlobalData highlighted that Eli Lilly reported its synthetic peptide Mounjaro had $980 million in global sales in Q2. trillion in the Q1 of 2023 to $3.56
It is one of the leading causes of death associated with AMR globally. Using this approach, our lead programme – RVX 001, a protein-based vaccine against invasive pneumococcal disease – has been designed with antigens common to all pneumococcus serotypes. References World Health Organization. 2022 [cited May2023].
Fierce Pharma just reported, “a big question hanging over AbbVie CEO Richard Gonzalez is whether he can lead the Illinois pharma safely through the patent cliff of its revenue cornerstone Humira. sales until at least 2023 because 257 patent filings stand in the way. In fact, Richard Gonzalez, C.E.O.
These figures are only expected to grow in the coming years, with sales forecasted to reach over $150 billion by 2028. Checkpoint modulators and cell therapies lead the way in the pre-registration stage, which features no cancer vaccines and oncolytic virus-focused therapies, she added.
This growth is expected to continue, with a 62% growth in annual consensus sales forecast from 2023 to 2028, fuelled by the company’s semaglutide portfolio, according to GlobalData’s report, ‘Looking ahead to 2023 – the future of pharma’. Johnson & Johnson maintained its leading position despite a decline of 12.8%
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content